Drug companies and managed care organizations are working to keep prices from rising precipitously. Then there’s Pfizer.
There’s been a sharp drop in Pharmaceutical deals in the first quarter of 2017, compared with a year ago. What’s up with that?
On March 11, Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that an experimental rheumatoid arthritis therapy (salrilumab) helped patients more than AbbVie Inc.’s (NYSE: ABBV) Humira in a late-stage trial. But AbbVie already had a new deal in place, a collaboration with Boehringer Ingelheim, that was announced on March 7. Under terms of the agreement, AbbVie […]